Dexmedetomidine and Intelligence Development in Pediatric Patients Undergoing Craniotomy

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

February 29, 2016

Study Completion Date

June 30, 2016

Conditions
Brain Neoplasms
Interventions
DRUG

dexmedetomidine

A loading dose dexmedetomidine (0.5 ug/kg IV infused in 15 minutes) will be administered after anesthesia induction, followed by a continuous infusion at a rate of 0.5 ug/kg/h until the closure of the brain duramater at the end of surgery.

DRUG

normal saline

Normal saline will be administered in the same rate, volume and duration as that in the dexmedetomidine group

Trial Locations (1)

100034

Department of Anesthesiology and Critical Care Medicine, Peking University First Hospital, Beijing

All Listed Sponsors
collaborator

Beijing Tiantan Hospital

OTHER

lead

Peking University First Hospital

OTHER

NCT02810899 - Dexmedetomidine and Intelligence Development in Pediatric Patients Undergoing Craniotomy | Biotech Hunter | Biotech Hunter